Search
CIGB 300
go.drugbank.com/drugs/DB16464InvestigationalCIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma
Piclidenoson
go.drugbank.com/drugs/DB05511InvestigationalCF 101 (known generically as IB-MECA) is an anti-inflammatory drug for rheumatoid arthritis patients. Its novel mechanism of action relies on antagonism of adenoside A3 receptors. … CF101 is supplied as an oral drug and has an excellent safety profile.
Jaktinib
go.drugbank.com/drugs/DB17545InvestigationalJaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.).
MK-0731
go.drugbank.com/drugs/DB08037InvestigationalMK-0731 is a kinesin spindle protein inhibitor and antineoplastic agent.
Osilodrostat
go.drugbank.com/drugs/DB11837ApprovedInvestigationalhas not been curative. … [L12123] It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsAcetarsol
go.drugbank.com/drugs/DB13268ApprovedWithdrawnAcetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties. … [L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964.
Aminophenazone
go.drugbank.com/drugs/DB01424ApprovedWithdrawnIn biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to measure the cytochrome P-450 metabolic activity in liver function tests.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: 1-Phenyl-2,3-dimethyl-4-(dimethylamino)-5-pyrazolone, 1-Phenyl-2,3-dimethyl-4-dimethylaminopyrazol-5-oneBHV-1300
go.drugbank.com/drugs/DB22673InvestigationalBHV-1300 is a IgG<sub>1,2,4</sub> selective degrader being investigated for the treatment of Grave's disease.
Milsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigational[A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes. … [L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]
Categories: Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT2 Receptor AntagonistsZedenoleucel
go.drugbank.com/drugs/DB18639InvestigationalMT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy.